Adalvo announces successful Pivotal BE outcome of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet

08 November 2021

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and will proceed with regulatory submission as soon as possible.

Our niche peptide product has been developed based on the reference brand Minirin Melt from Ferring which is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis and nocturia. The brand sold $110mio globally in 2020, according to IQVIA.

Adalvo is one of the very few companies working on this niche peptide product which demonstrates our ability to continuously offer highly differentiated, value-added niche products to our partners.